GLP-1 agonists

About Topics

Topics include original Beta Cells in Diabetes content, as well as expert-selected resources chosen by our Editorial Board.

Home › GLP-1 Agonists

Case 5: Graduate Student with Atypical Symptoms

Tags: , , , , , ,
A 25-year-old graduate student originally presented to you with symptoms of a UTI. An urinanalysis showed signs of infection, as well as glycosuria.

Diabetes Agents and Carcinogenesis

Posted October 5, 2011 by Irl B. Hirsch, MD
Tags:

It is difficult to forget the dramatic controversy that occurred in the summer of 2009 when four observational studies[1] were published in the journal Diabetologia three of which suggested an association between insulin glargine and certain forms of cancer. 

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.

Elashoff, Michael; Matveyenko, Aleksey V; Gier, Belinda; Elashoff, Robert; Butler, Peter C
Gastroenterology; 2011 Jul;141(1):150-6. PMID: 21334333;
Category: Interventions;
Tags:

Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies.

Renehan, Andrew G; Tyson, Margaret; Egger, Matthias; Heller, Richard F; Zwahlen, Marcel
Lancet; 2008 Feb 16;371(9612):569-78. PMID: 18280327;
Category: Interventions;
Tags:

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations.

Bennett, Wendy L; Maruthur, Nisa M; Singh, Sonal; Segal, Jodi B; Wilson, Lisa M; Chatterjee, Ranee; Marinopoulos, Spyridon S; Puhan, Milo A; Ranasinghe, Padmini; Block, Lauren; Nicholson, Wanda K; Hutfless, Susan; Bass, Eric B; Bolen, Shari
Annals of internal medicine; 2011 May 3;154(9):602-13. PMID: 21403054;
Category: Interventions;
Tags: , , , , ,

Can Current Drug Therapy Prevent Beta Cell Failure and Bring Treatment Durability in T2DM?

Posted July 20, 2011 by John L. Leahy, MD
Tags: , , , , , , ,

A hot topic in the type 2 diabetes world is whether we have in hand the tools to stop the decline in beta cell function that typifies this disease and, consequently, a therapy or therapies that successfully control blood glucose for many years – so-called treatment durability.

Calcineurin signaling regulates human islet {beta}-cell survival.

Soleimanpour, Scott A; Crutchlow, Michael F; Ferrari, Alana M; Raum, Jeffrey C; Groff, David N; Rankin, Matthew M; Liu, Chengyang; De León, Diva D; Naji, Ali; Kushner, Jake A; Stoffers, Doris A
The Journal of biological chemistry; 2010 Dec 17;285(51):40050-9. PMID: 20943662;
Category: Interventions / GLP-1s;
Tags: ,

Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function.

Park, Sunmin; Dong, Xiaocheng; Fisher, Tracy L; Dunn, Sarah; Omer, A Kadir; Weir, Gordon; White, Morris F
The Journal of biological chemistry; 2006 Jan 13;281(2):1159-68. PMID: 16272563;
Category: Interventions / GLP-1s;
Tags:

The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice.

Rolin, Bidda; Larsen, Marianne O; Gotfredsen, Carsten F; Deacon, Carolyn F; Carr, Richard D; Wilken, Michael; Knudsen, Lotte Bjerre
American journal of physiology. Endocrinology and metabolism; 2002 Oct;283(4):E745-52. PMID: 12217892;
Category: Interventions / GLP-1s;
Tags:

Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice.

Wang, Q; Brubaker, P L
Diabetologia; 2002 Sep;45(9):1263-73. PMID: 12242459;
Category: Interventions / GLP-1s;
Tags:
  • Page 1 of 4
  •  
  • Next
|